These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30550035)

  • 1. [The pathway of vasopressin as a pharmacological target in nephrology: a narrative review].
    Recupero M; Fulignati P; Naticchia A; D'Alonzo S; D'Ascenzo F; Costanzi S
    G Ital Nefrol; 2018 Dec; 35(6):. PubMed ID: 30550035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vasopressin receptor antagonists: the vaptans].
    Villabona C
    Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on tolvaptan for autosomal dominant polycystic kidney disease.
    Poch E; Rodas L; Blasco M; Molina A; Quintana L
    Drugs Today (Barc); 2018 Sep; 54(9):519-533. PubMed ID: 30303493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical review: the use of vaptans in clinical endocrinology.
    Peri A
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current options of treatment of hyponatremia].
    Tesař V
    Vnitr Lek; 2016; 62 Suppl 6():97-101. PubMed ID: 28124939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease.
    Devuyst O; Torres VE
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):459-70. PubMed ID: 23736843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyponatremia, fluid-electrolyte disorders, and the syndrome of inappropriate antidiuretic hormone secretion: diagnosis and treatment options.
    Siragy HM
    Endocr Pract; 2006; 12(4):446-57. PubMed ID: 16901803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of "Vaptans" in treatment of hyponatremia].
    Tanındı A; Töre HF
    Turk Kardiyol Dern Ars; 2015 Apr; 43(3):292-301. PubMed ID: 25906004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
    Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
    Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conivaptan therapy in an infant with severe hyponatremia and congestive heart failure.
    Sahu R; Balaguru D; Thapar V; Haque I; Pham-Peyton C; Bricker JT
    Tex Heart Inst J; 2012; 39(5):724-6. PubMed ID: 23109779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopressin antagonism: potential impact on neurologic disease.
    Rabinstein AA
    Clin Neuropharmacol; 2006; 29(2):87-93. PubMed ID: 16614541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyponatremia and cyst growth in neonatal polycystic kidney disease: a case for aquaretics?
    Bockenhauer D
    Pediatr Nephrol; 2017 May; 32(5):721-723. PubMed ID: 28194573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
    Lin TE; Adams KF; Patterson JH
    Heart Fail Clin; 2014 Oct; 10(4):607-20. PubMed ID: 25217436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arginine vasopressin antagonism in heart failure: Current status and possible new directions.
    Goldsmith SR
    J Cardiol; 2019 Jul; 74(1):49-52. PubMed ID: 30904236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of vaptans in the management of hyponatremia.
    Lehrich RW; Ortiz-Melo DI; Patel MB; Greenberg A
    Am J Kidney Dis; 2013 Aug; 62(2):364-76. PubMed ID: 23725974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of hyponatremia in acute illness.
    Schrier RW; Bansal S
    Curr Opin Crit Care; 2008 Dec; 14(6):627-34. PubMed ID: 19005303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
    Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?
    Fukui H
    World J Gastroenterol; 2015 Nov; 21(41):11584-96. PubMed ID: 26556988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C; Hutchinson DJ
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.